Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-EGFRvIII ADC 5
- Development stage
- Preclinical
- Lead developer
- AbTis
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
anti-EGFRvIII ADC 5 is an experimental antibody-drug conjugate (ADC) targeting the Epidermal Growth Factor Receptor variant III (EGFRvIII), specifically developed for the treatment of glioblastoma multiforme (GBM). It is a homogeneous conjugate with a drug-to-antibody ratio (DAR) of 4.0, produced using site-specific conjugation technology (AbClick). The drug is designed to overcome the limitations of conventional heterogeneous ADCs, which often contain highly loaded species that fail to penetrate the blood-brain barrier (BBB). By maintaining homogeneity and an optimal payload loading rate, anti-EGFRvIII ADC 5 demonstrates enhanced delivery of its cytotoxic payload, monomethyl auristatin E (MMAE), to brain tumor tissues, resulting in improved antitumor efficacy and survival in preclinical orthotopic models.
- Other names
- DH8.3-AbClick-MMAE (DAR 4.0)homogeneous anti-EGFRvIII ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))EGFRvIII (Epidermal growth factor receptor variant III)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on anti-EGFRvIII ADC 5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-EGFRvIII ADC 5.